You are here: Home » International » News » Companies
Business Standard

Bristol-Myers plans to buy Celgene for $74 bn to improve cancer portfolio

The deal will create a company with nine treatments bringing in more than $1 billion in annual sales and a significant potential for growth in oncology, immunology

Reuters 

UCLA, cancer drug

Squibb Co said on Thursday it would buy Corp for about $74 billion, creating a major pharma company with drugs as competition in the space heats up.

pioneered with its Yervoy and later Opdivo, but has come under pressure as Merck & Co's rival treatment Keytruda moved ahead in market share in lung treatment, the most lucrative oncology market.

The deal will create a company with nine treatments bringing in more than $1 billion in annual sales and a significant potential for growth in oncology, immunology and and

Talks opened in September, with approaching Celgene, according to a source familiar with the matter.

said the deal addresses a priority for to diversify from immunotherapy, calling the acquisition opportunistic but expensive.

"This proposed deal does not send a confident signal about Bristol's independent growth prospects," Arfaei said in a client note.

Increasing competition for treatments of both and clinical setbacks last year have resulted in investor concern over their future prospects.

Shares of have lost 38.6 percent of its value in 2018, while those of Bristol-Meyers have shed 15.2 percent.

Last year, bought drug developer for $9 billion, betting on its chimeric antigen receptor T-cell therapy, known as CAR-T, in a bid to reduce reliance on its mainstay drug, Revlimid.

Brad Loncar, of Loncar Investments, said both have made significant mistakes and poor investments in acquisitions and partnerships with smaller

"Both of them were coming into this year kind of limping. Merging together makes the combined entity a lot stronger," said Loncar, whose firm runs the Loncar Cancer ETF.

Celgene shareholders will receive one share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 percent to Celgene's Wednesday close.

Bristol-Myers shares fell 9.5 percent at $47.10, while Celgene shares rose 33.5 percent at $88.95 in premarket trading.

Celgene shareholders will also receive one tradeable contingent value right for each share held, which will entitle them to receive a one-time potential payment of $9 in cash upon regulatory approval of ozanimod and liso-cel by Dec. 31, 2020 and bb2121 by March 31, 2021.

Bristol-Myers said it expects to speed up a share repurchase program of up to about $5 billion, subject to the closing of the transaction, market conditions and board approval.

The companies expect to close the deal in the third quarter of 2019. The cash portion will be funded through a combination of cash on hand and debt financing.

The deal is expected to add more than 40 percent to Bristol-Myers's earnings on a standalone basis in the first full year after the deal closes.

Bristol-Myers has obtained fully committed debt financing from and Bank Ltd.

is the to Bristol-Myers, and Evercore and are its financial advisers. is its

is serving as and is the to Celgene. Wachtell, Lipton, is its

 

 

First Published: Thu, January 03 2019. 20:21 IST
RECOMMENDED FOR YOU